Liu, Yaping http://orcid.org/0000-0003-4165-7693
Reed, Sarah C.
Lo, Christopher
Choudhury, Atish D. http://orcid.org/0000-0001-9344-6631
Parsons, Heather A. http://orcid.org/0000-0001-8178-6612
Stover, Daniel G. http://orcid.org/0000-0001-9003-8165
Ha, Gavin http://orcid.org/0000-0001-7578-7272
Gydush, Gregory
Rhoades, Justin
Rotem, Denisse
Freeman, Samuel http://orcid.org/0000-0001-8285-0057
Katz, David W. http://orcid.org/0000-0002-4357-443X
Bandaru, Ravi http://orcid.org/0009-0004-8398-8348
Zheng, Haizi http://orcid.org/0000-0001-6165-0179
Fu, Hailu http://orcid.org/0000-0003-0461-3552
Adalsteinsson, Viktor A. http://orcid.org/0000-0003-4555-2485
Kellis, Manolis http://orcid.org/0000-0001-7113-9630
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R56HG012360)
Article History
Received: 14 April 2023
Accepted: 22 March 2024
First Online: 30 March 2024
Competing interests
: Y.L., V.A.A. and M.K. have an approved patent covered FinaleMe (“Methods for genome characterization”, US Patent US11788135B2, date of patent, Oct 17, 2023, filed by MIT and Broad Institute of MIT and Harvard). Y.L. owns stocks from Freenome Inc. V.A.A., G.H. and S.F. are inventors on an approved patent covered ichorCNA (US20190078232A1, “Methods for genome characterization”, date of patent, Mar 14, 2019, filed by Harvard College, Dana Farber Cancer Institute Inc, Broad Institute of MIT and Harvard) on methods for estimating tumor fraction in cfDNA. VAA is a co-inventor on a patent application covering MAESTRO (US 2023/0203568, “Minor allele enrichment sequencing through recognition oligonucleotides”, pending, filed by Broad Institute of MIT and Harvard), which has been licensed to Exact Sciences, receives sponsored research funding from Exact Sciences, and is a cofounder and advisor to Amplifyer. The remaining authors declare no competing interests. H.Z is currently an employee at Regeneron Pharmaceuticals Inc. and contributed to this article as an employee of Cincinnati Children’s Hospital Medical Center, and the views expressed do not necessarily represent the views of Regeneron Pharmaceuticals Inc.